Genmab — December 2020
-
-
Endpoint news: BCMA bawl: https://endpts.com/ash20-saw-a-bcma-brawl-whos-still-standing-and-who-got-knocked-out-for-good/
-
Kan du give et kort sum-op @Sukkeralf. Det kræver medlemskab at læse artiklen.
-
"I think broadly now, that we’ve seen whenever we add daratumumab to the standard of care, whatever that may be, we seem to see a significant improvement in progression-free survival and improving depth of response,” he said. https://www.hcplive.com/view/daratumumab-pomalidomide-relapsed-refractory-multiple-myeloma
-
Legolas ikke så meget nyt - artiklen mener nok at JNJ/Legends CAR-T er i førertrøjen omend de døjer med lidt neurotox. Regenron og JNJs BaAbs kommer vel ind som nummer to. Amgens BsAbs lider begge. BCMA ADC har for lav responsrate og AEs, hvor specielt ocular tox er et problem. Så ingen direkte vinder endnu....
-
No, I think it is only for people registered for ASH
-
talking about analysts, i was a bit surprised that Sydbank had not yet included anything on epco "Han har endnu ikke har indregnet de nye midler som eksempelvis epicoritamab i sine egne modeller, men siger at de også kommer med i beregningerne i takt med at flere data bliver offentliggjort" https://www.euroinvestor.dk/nyheder/sydbank-saerdeles-positive-data-fra-genmabs-nye-studie
-
-
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind